Melanoma immunotherapy

Cancer Biology and Therapy

Volumn 15, Issue 6, 2014, Pages 665-674

  Sanlorenzo, Martina ^a,b   Vujic, Igor ^a,c   Posch, Christian ^a,c   Dajee, Akshay ^a   Yen, Adam ^a   Kim, Sarasa ^a   Ashworth, Michelle ^a   Rosenblum, Michael D ^a   Algazi, Alain ^a   Osella Abate, Simona ^b   Quaglino, Pietro ^b   Daud, Adil ^a   Ortiz Urda, Susanna ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Anti PD 1; CTLA 4; Immunoprofiling; Interferons; Interleukins; Ipilimumab; PD 1

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CARBOPLATIN; CISPLATIN; CP 870893; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; OX40 LIGAND; PACLITAXEL; PEMBROLIZUMAB; PEPTIDE VACCINE; STAT1 PROTEIN; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; VINBLASTINE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TUMOR MARKER;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; BIOCHEMOTHERAPY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CHEMOTHERAPY; ELECTROPORATION; HUMAN; IN-TRANSIT METASTASIS; LYMPHOCYTE ACTIVATION; MELANOMA; NATURAL KILLER CELL; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE; IMMUNOLOGY; METABOLISM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84901722771     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28555     Document Type: Review

References (77)

1. Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone B, Fierro MT, Savoia P, Bernengo MG. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol 2010; 21:409-14; PMID:19622589; http://dx.doi.org/10.1093/annonc/mdp325
2. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6(Suppl 1):S11-4; PMID:10685652
3. Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 2013; 62:1021-8; PMID:23591982; http://dx.doi.org/10.1007/s00262-013- 1418-6
4. Eklund JW, Kuzel TM. A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 2004; 16:542-6; PMID:15627015; http://dx.doi.org/10.1097/01.cco.0000142070.45097.68
5. Mekhail T, Wood L, Bukowski R. Interleukin-2 in cancer therapy: uses and optimum management of adverse effects. BioDrugs 2000; 14:299-318; PMID:18034575; http://dx.doi.org/10.2165/00063030-200014050-00003
6. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013
7. Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 2012; 35:66-72; PMID:22130161; http://dx.doi.org/10.1097/CJI. 0b013e3182372636
8. Boyd KU, Wehrli BM, Temple CLF. Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol 2011; 104:711-7; PMID:21744347; http://dx.doi.org/10.1002/jso.21968
9. Grotz TE, Mansfield AS, Kottschade LA, Erickson LA, Otley CC, Markovic SN, Jakub JW. In-transit melanoma: an individualized approach. Oncology (Williston Park) 2011; 25:1340-8; PMID:22329185
10. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003; 89:1620-6; PMID:14583759; http://dx.doi.org/10.1038/sj.bjc.6601320
11. Ridolfi L, Ridolfi R, Ascari-Raccagni A, Fabbri M, Casadei S, Gatti A, Trevisan G, Righini MG. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients. J Eur Acad Dermatol Venereol 2001; 15:218-23; PMID:11683284; http://dx.doi.org/10.1046/j.1468-3083.2001.00254.x
12. Parker SE, Khatibi S, Margalith M, Anderson D, Yankauckas M, Gromkowski SH, Latimer T, Lew D, Marquet M, Manthorpe M, et al. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther 1996; 3:175-85; PMID:8725882
13. Heller R, Shirley S, Guo S, Donate A, Heller L. Electroporation based gene therapy-from the bench to the bedside. Conf Proc Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Conf 2011; 2011:736-8.
14. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26:5896-903; PMID:19029422
15. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011; 17:2619-27; PMID:21372217; http://dx.doi.org/10.1158/1078- 0432.CCR-10-1114
16. Sarasin-Filipowicz M, Oakeley EJ, Duong FHT, Christen V, Terracciano L, Filipowicz W, Heim MH. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105:7034-9; PMID:18467494; http://dx.doi.org/10.1073/pnas.0707882105
17. Lee C-K, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol 2000; 165:3571-7; PMID:11034357
18. Avalle L, Pensa S, Regis G, Novelli F, Poli V. STAT1 and STAT3 in tumorigenesis: A matter of balance. JAKSTAT 2012; 1:65-72; PMID:24058752; http://dx.doi.org/10.4161/jkst.20045
19. Baker DE. Pegylated interferons. Rev Gastroenterol Disord 2001; 1:87-99; PMID:12120178
20. Payne MJ, Argyropoulou K, Lorigan P, McAleer JJ, Farrugia D, Davidson N, Kelly C, Chao D, Marshall E, Han C, et al. Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol 2014; 32:185-90; PMID:24344211; http://dx.doi.org/10.1200/JCO.2013.49.8717
21. Sasse AD, Sasse EC, Clark LGO, Ulloa L, Clark OAC. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007; CD005413; PMID:17253556
22. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a metaanalysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25:5426-34; PMID:18048825; http://dx.doi.org/10.1200/JCO.2007.12.0253
23. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, et al. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 2009; 19:42-9; PMID:19430405; http://dx.doi.org/10.1097/CMR.0b013e328314b84a
24. Flaherty LE, Moon J, Atkins MB, Tuthill R, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, et al. Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG. J Clin Oncol [Internet] 2012 [cited 2014 Jan 21]; 30. Available from: http://meetinglibrary.asco.org/content/92968-114
25. Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Di Nardo A, Kabigting FD, Dasanu CA. Immunotherapy for melanoma: current status and perspectives. J Immunother 2010; 33:570-90; PMID:20551839; http://dx.doi.org/10. 1097/CJI.0b013e3181e032e8
26. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90:1894-900; PMID:9862627; http://dx.doi.org/10.1093/jnci/90.24.1894
27. Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190:1669-78; PMID:10587357; http://dx.doi.org/10.1084/jem.190.11.1669
28. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know. Nat Rev Clin Oncol 2011; 8:577-85; PMID:21808266; http://dx.doi.org/10.1038/nrclinonc.2011.116
29. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, et al. Clinical responses in a phase II study using adoptive transfer of shortterm cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010; 16:2646-55; PMID:20406835; http://dx.doi.org/10.1158/1078-0432.CCR-10-0041
30. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449
31. Dudley ME, Gross CA, Somerville RPT, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 2013; 31:2152-9; PMID:23650429; http://dx.doi.org/10.1200/JCO.2012.46.6441
32. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012; 18:6758-70; PMID:23032743; http://dx.doi.org/10.1158/1078-0432.CCR-12-1177
33. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116
34. Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 2013; 19:4792-800; PMID:23690483; http://dx.doi.org/10.1158/ 1078-0432.CCR-13-0380
35. Home - ClinicalTrials.gov [Internet]. [cited 2013 Sep 18]; Available from: http://clinicaltrials.gov/
36. Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 2009; 229:67-87; PMID:19426215; http://dx.doi.org/10.1111/j.1600-065X.2009.00763.x
37. Shah KV, Chien AJ, Yee C, Moon RT. CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J Invest Dermatol 2008; 128:2870-9; PMID:18563180; http://dx.doi.org/10.1038/jid.2008.170
38. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; http://dx.doi.org/10.1016/S1470-2045(09)70334-1
39. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
40. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
41. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18:2039-47; PMID:22271879; http://dx.doi.org/10.1158/1078-0432.CCR-11-1823
42. Ribas A, Kefford R, Marshall MA, Punt CJA, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616-22; PMID:23295794; http://dx.doi.org/10.1200/JCO.2012.44.6112
43. Simeone E, Ascierto PA. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol 2012; 9:241-7; PMID:22524673; http://dx.doi.org/10.3109/ 1547691X.2012.678021
44. Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G, et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 2011; 17:896-906; PMID:21106722; http://dx.doi.org/10.1158/1078-0432.CCR-10-2463
45. Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001; 22:265-8; PMID:11323285; http://dx.doi.org/10.1016/S1471-4906(01)01888-9
46. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19:813-24; PMID:17606980; http://dx.doi.org/10. 1093/intimm/dxm057
47. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12:492-9; PMID:21739672; http://dx.doi.org/10.1038/ni.2035
48. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
49. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R-A, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
50. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
51. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
52. Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, Boasberg PD, Flaherty K, Hwu P, Ballinger M, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol [Internet] 2013 [cited 2013 Sep 18]; 31. Available from: http://meetinglibrary.asco.org/content/ 115916-132
53. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007; 25:876-83; PMID:17327609; http://dx.doi.org/10.1200/JCO.2006.08.3311
54. Nowak AK, Robinson BWS, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63:4490-6; PMID:12907622
55. Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013; 2:e23033; PMID:23483678; http://dx.doi.org/10.4161/onci. 23033
56. Ascierto PA, Simeone E, Sznol M, Fu Y-X, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37:508-16; PMID:21074066; http://dx.doi.org/10.1053/j.seminoncol.2010.09.008
57. Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Science gone translational: the OX40 agonist story. Immunol Rev 2011; 244:218-31; PMID:22017441; http://dx.doi.org/10.1111/j.1600-065X.2011.01069.x
58. Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen H-R, Pyle KJ, Hipkiss E, Vignali DAA, Pardoll DM, Drake CG. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009; 182:6659-69; PMID:19454660; http://dx.doi.org/10.4049/jimmunol.0804211
59. Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, Triebel F, Charron D, Aoudjit F, Al-Daccak R, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 2011; 186:5173-83; PMID:21441454; http://dx.doi.org/10.4049/jimmunol. 1002050
60. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207:2187-94; PMID:20819927; http://dx.doi.org/10.1084/jem.20100643
61. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19:3477-82; PMID:11481353
62. Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009; 27:2645-52; PMID:19364969; http://dx.doi.org/10. 1200/JCO.2008.19.1106
63. Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, Deneux L, Gorin I, Negrier S, Mathiot C, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996; 14:1697-703; PMID:8622090
64. Kirkwood JM, Tarhini AA. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol 2009; 27:2583-5; PMID:19364958; http://dx.doi.org/10.1200/JCO.2008.21.1540
65. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ Jr., Rosenberg SA. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004; 173:7125-30; PMID:15585832
66. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 2005; 28:258-67; PMID:15838383; http://dx.doi.org/10.1097/01.cji. 0000158855.92792.7a
67. Powell DJ Jr., Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005; 105:241-50; PMID:15345595; http://dx.doi.org/10.1182/blood-2004-06-2482
68. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005; 175:7046-52; PMID:16272366
69. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202:907-12; PMID:16203864; http://dx.doi.org/10.1084/jem.20050732
70. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13:6681-8; PMID:17982122; http://dx.doi.org/10.1158/1078-0432.CCR-07-0187
71. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-53; PMID:16087944; http://dx.doi.org/10.1200/JCO.2005.06.205
72. Ku GY, Yuan J, Page DB, Schroeder SEA, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116:1767-75; PMID:20143434; http://dx.doi.org/10.1002/cncr.24951
73. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010; 37:473-84; PMID:21074063; http://dx.doi.org/10.1053/j.seminoncol.2010.09. 001
74. Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012; 2:765; PMID:23097687; http://dx.doi.org/10.1038/srep00765
75. Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J, Fox BA. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med 2013; 11:54; PMID:23452415; http://dx.doi.org/10.1186/1479-5876-11-54
76. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011; 9:204; PMID:22123319; http://dx.doi.org/10.1186/1479-5876-9-204
77. Weber JS, Kudchadkar RR, Gibney GT, Conti RCD, Yu B, Wang W, Sarnaik A, Martinez AJ, Kroeger J, Eysmans C, et al. Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab. J Clin Oncol [Internet] 2013 [cited 2013 Sep 18]; 31. Available from: http://meetinglibrary.asco.org/content/112287-132